Abstract:With the development of molecular pathology, many types of epidermal growth factor receptor (EGFR) mutations have been identified. The efficacy of EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC) patients with different types of EGFR mutations, especially in patients with single rare mutations or complex mutations (co-occurrence of two or more different mutations), has not been fully understood. This study aimed to examine the efficacy of EGFR-TKIs in NSCLC patients with different types of EGFR mutations. Clinical data of 809 NSCLC patients who harbored different types of EGFR mutations and treated from January 2012 to October 2016 at Renmin Hospital and Zhongnan Hospital, Wuhan, were retrospectively reviewed. The clinical characteristics of these patients and the efficacy of EGFR-TKIs were analyzed. Among these patients, 377 patients had only the EGFR del-19 mutation, 362 patients the EGFR L858R mutation in exon 21, 33 patients single rare mutations and 37 patients complex mutations. Among these 809 patients, 239 patients were treated with EGFR-TKIs. In all the 239 patients, the disease control rate (DCR) was 93.7% with two patients (0.2%) achieving complete response (CR), the median progression free survival (PFS) was 13.0 months (95% confidence interval [CI], 11.6–14.4 months), and the median overall survival (OS) was 55.0 months (95% CI, 26.3–83.7 months). Subgroup analysis revealed that the DCR in patients harboring single rare or complex mutations of EGFR was significantly lower than in those with del-19 or L858R mutation (P<0.001). Patients with classic mutations (del-19 and/or L858R mutations) demonstrated longer PFS (P<0.001) and OS (P=0.017) than those with uncommon mutations (single rare and/or complex mutations). Furthermore, the patients with single rare mutations had shorter median OS than in those with other mutations. Multivariate Cox regression analysis identified that the type of EGFR mutations was an independent risk factor for PFS (hazard ratio [HR]=0.308, 95% CI, 0.191–0.494, P<0.001) and OS (HR=0.221, 95% CI, 0.101–0.480, P<0.001). The results suggest that the single rare or complex EGFR mutations confer inferior efficacy of EGFR-TKIs treatment to the classic mutations. The prognosis of the single rare EGFR mutations is depressing. EGFR-TKIs may be not a good choice for NSCLC patients with single rare mutations of EGFR. Further studies in these patients with uncommon mutations (especially for the patients with single rare mutations) are needed to determine a better precision treatment.

Effectiveness of Tyrosine Kinase Inhibitors on Uncommon Epidermal Growth Factor Receptor Mutations in Non-small Cell Lung Cancer

Uncommon EGFR Mutations in a Cohort of Chinese NSCLC Patients and Outcomes of First-Line EGFR-TKIs and Platinum-Based Chemotherapy.

Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients

Analysis of Effectiveness of Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations Containing Rare Mutations

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes after Treatment with EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

Efficacy of Targeted Therapy in Patients with Non-Small Cell Lung Cancer Harboring Very Rare Mutations in EGFR Exon 18

The Predictive Value of Uncommon EGFR Mutation in Patients with Non-Small-cell Lung Cancer.

Treatment of Uncommon EGFR Mutations in Non-Small Cell Lung Cancer: New Evidence and Treatment

EGFR Tyrosine Kinase Inhibitor (TKI) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring Uncommon EGFR Mutations: A Real-World Study in China.

Outcomes in non‐small cell lung cancer with uncommon epidermal growth factor receptor L858 substitutions under first‐line epidermal growth factor receptor tyrosine kinase inhibitors: A large real‐world cohort study

Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)

EGFR Uncommon Alterations in Advanced Non-Small Cell Lung Cancer and Structural Insights into Sensitivity to Diverse Tyrosine Kinase Inhibitors.

P76.98 NSCLC Patients with Rare EGFR Mutations in Exons 18 and 19 Benefits from Treatment with EGFR Tyrosine Kinase Inhibitors

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors …

Efficacy of First-Generation EGFR-TKIs on Patients with NSCLC Harboring EGFR Uncommon Mutations: a Pooled Analysis

Efficacy of EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Patients Harboring Different Types of EGFR Mutations: A Retrospective Analysis

Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients

Clinical features and outcomes of unresectable locally advanced non-small cell lung cancer with uncommon EGFR Mutations: A retrospective multi-center Chinese study

Clinical Efficacy Evaluation of Tyrosine Kinase Inhibitors for Non-Adenocarcinoma Lung Cancer Patients Harboring Egfr-Sensitizing Mutations

Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis